Eli Lilly Enters Definitive Agreement to Acquire Centessa Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Acquisition Agreement Details: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, reflecting a strong endorsement of Centessa's promising drug pipeline.
- Potential Value Enhancement: Centessa shareholders will receive a non-transferable contingent value right that could yield an additional $9.00 per share if three specified milestones are achieved, raising the total potential value to $47.00 per share and incentivizing shareholder support for the transaction.
- Positive Market Reaction: Centessa's shares surged 47% to $40.50 in premarket trading, indicating strong market optimism regarding the acquisition and confidence in the company's drug development prospects.
- Drug Development Outlook: Centessa's lead candidate, cleminorexton, has shown best-in-class potential in clinical trials for narcolepsy, and Lilly's acquisition is expected to accelerate the commercialization of this drug, enhancing Lilly's competitive position in the neurological drug market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 878.240
Low
950.00
Averages
1192
High
1500
Current: 878.240
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
Surge in Oil Prices Triggers Market Volatility
- Oil Price Impact: The average gas price in the U.S. has surpassed $4 per gallon for the first time since 2022, indicating that the surge in crude oil prices due to the U.S.-Iran conflict is putting pressure on the market, with all three major indexes on track for their worst monthly and quarterly performance since 2022.
- Fed Policy Stability: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, stating that the current rate target is 'a good place,' which led to a sharp decline in rate hike odds among traders and alleviated inflation concerns.
- Real Estate Market Consolidation: Opendoor is acquiring parts of Doma to leverage artificial intelligence in reducing real estate closing costs, particularly as mortgage refinancing applications decline, potentially enhancing its competitive edge in the market.
- Pharmaceutical Industry Competition: Novo Nordisk is launching multi-month Wegovy subscriptions to catch up with Eli Lilly in the GLP-1 market, with longer-term packages expected to save users hundreds of dollars, intensifying the competition between the two companies.
See More
Eli Lilly Acquires Centessa Pharmaceuticals to Enhance Neuroscience Portfolio
- Acquisition Overview: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38 per share in cash, valuing the transaction at approximately $6.3 billion, with a contingent value right (CVR) potentially raising the total consideration to $47 per share, indicating strong confidence in Centessa.
- Strategic Expansion: This acquisition aims to enhance Lilly's market presence in neuroscience and sleep disorder treatments, particularly targeting experimental therapies for excessive daytime sleepiness and related neurological conditions, thereby diversifying its product pipeline.
- Positive Market Reaction: Following the announcement, Centessa Pharmaceuticals' stock surged over 46% in Tuesday's premarket trading, reflecting the market's favorable view of the deal and recognition of future growth potential.
- Potential Value Increase: The CVR could add approximately $1.5 billion in additional equity value to the transaction, further enhancing Centessa's attractiveness and indicating Lilly's optimistic outlook on its future research and development outcomes.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Novo Nordisk Launches Wegovy Drug Subscription Program
- Subscription Program Launch: Novo Nordisk has introduced a multi-month subscription program for its Wegovy obesity drug, aiming to provide cash-paying patients with lower, predictable monthly prices, with potential annual savings of up to $1,200.
- Flexible Options: Patients can choose from three, six, or twelve-month subscriptions, with lower monthly fees for both the injection and the newly launched pill, priced at $329 for three months, $299 for six months, and $249 for twelve months for the injection.
- Competitive Market Pressure: Following the explosive uptake of Novo's pill since its U.S. launch in January, it is set to face competition from Eli Lilly's upcoming oral GLP-1, which currently holds a 60% market share in the U.S.
- Patient Support Strategy: Novo emphasizes that the subscription program not only aids patients in starting therapy but also helps them manage pricing fluctuations during treatment, aiming to enhance long-term adherence to obesity treatment.
See More
Surge in Oil Prices Triggers Market Volatility
- Oil Price Impact: The average gas price in the U.S. has surpassed $4 per gallon for the first time since 2022, indicating that the surge in crude oil prices due to the U.S.-Iran conflict is putting pressure on the market, with all three major indexes on track for their worst monthly and quarterly performance since 2022.
- Fed Policy Stability: Federal Reserve Chair Jerome Powell reassured investors at Harvard University that rising oil prices would not necessitate interest rate hikes, stating that the current rate target is 'a good place,' which led to a sharp decline in rate hike odds among traders and alleviated inflation concerns.
- Real Estate Market Consolidation: Opendoor is acquiring parts of Doma to leverage artificial intelligence in reducing real estate closing costs, particularly as mortgage refinancing applications decline, potentially enhancing its competitive edge in the market.
- Pharmaceutical Industry Competition: Novo Nordisk is launching multi-month Wegovy subscriptions to catch up with Eli Lilly in the GLP-1 market, with longer-term packages expected to save users hundreds of dollars, intensifying the competition between the two companies.
See More
Eli Lilly Acquires Centessa Pharmaceuticals to Enhance Neuroscience Portfolio
- Acquisition Overview: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38 per share in cash, valuing the transaction at approximately $6.3 billion, with a contingent value right (CVR) potentially raising the total consideration to $47 per share, indicating strong confidence in Centessa.
- Strategic Expansion: This acquisition aims to enhance Lilly's market presence in neuroscience and sleep disorder treatments, particularly targeting experimental therapies for excessive daytime sleepiness and related neurological conditions, thereby diversifying its product pipeline.
- Positive Market Reaction: Following the announcement, Centessa Pharmaceuticals' stock surged over 46% in Tuesday's premarket trading, reflecting the market's favorable view of the deal and recognition of future growth potential.
- Potential Value Increase: The CVR could add approximately $1.5 billion in additional equity value to the transaction, further enhancing Centessa's attractiveness and indicating Lilly's optimistic outlook on its future research and development outcomes.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
